Regenxbio (RGNX) Current Assets (2014 - 2026)

Regenxbio's Current Assets history runs 12 years deep, the most recent figure standing at $281.3 million for Q4 2025.

• In Q4 2025, Current Assets rose 1.18% year-over-year to $281.3 million; the TTM figure through Dec 2025 stood at $281.3 million (up 1.18% YoY), while the FY2025 annual figure was $281.3 million, up 1.18% from the prior year.
• Current Assets for Q4 2025 stood at $281.3 million, down from $332.0 million in the prior quarter.
• The five-year high for Current Assets was $518.8 million in Q4 2021, with the low at $278.0 million in Q4 2024.
• The 5-year median for Current Assets is $384.0 million (2023), against an average of $386.6 million.
• The sharpest annual moves came in 2021 and 2025: Current Assets surged 47.42% in 2021, then decreased 20.78% in 2025.
• Regenxbio's Current Assets stood at $518.8 million in 2021, then dropped by 19.82% to $416.0 million in 2022, then declined by 19.47% to $335.0 million in 2023, then retreated by 17.01% to $278.0 million in 2024, then increased by 1.18% to $281.3 million in 2025.
• Business Quant data shows RGNX's Current Assets at $281.3 million in Q4 2025, $332.0 million in Q3 2025, and $373.8 million in Q2 2025.